Form 4: Nurix Therapeutics Chief Legal Officer Reports Routine Equity Transactions

Nurix Therapeutics' Chief Legal Officer, Christine Ring, reported the vesting of restricted stock units and a subsequent 'sell to cover' transaction to satisfy tax obligations.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on July 30, 2025.
• Acquired a total of 10,532 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
• Disposed of 3,841 shares of common stock at a weighted average sale price of $12.011, with individual sales ranging from $11.78 to $12.315.
• The sale was a non-discretionary 'sell to cover' transaction mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations related to RSU vesting.
• Following these transactions, Christine Ring beneficially owns 44,009 shares of Nurix Therapeutics common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive because the transactions represent the vesting of equity compensation for a key executive, indicating continued alignment of interests. The sale was non-discretionary ('sell to cover' for taxes), which does not imply a negative outlook on the company's future performance.

Positives

• Vesting of 10,532 Restricted Stock Units indicates continued equity compensation for a key executive, aligning management interests with shareholders.
• The 'sell to cover' transaction is not a discretionary sale, suggesting no negative sentiment from the executive regarding the company's future prospects.

Negatives

• A reduction of 3,841 shares in direct beneficial ownership due to the 'sell to cover' transaction.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing is a routine insider transaction report for an executive at a biotechnology company. Such transactions are common for executives receiving equity compensation and do not typically reflect broader industry trends, though the company's stock performance (reflected in the sale price) is influenced by the biotech sector's overall health.

Stakeholder Impact

• Shareholders: The 'sell to cover' transaction results in a minor reduction in direct beneficial ownership, but the overall impact is minimal given the routine nature and small volume relative to total shares outstanding. The continued equity compensation for a key executive aligns management interests with shareholders.
• Employees: The RSU vesting demonstrates the company's ongoing equity compensation practices for its executives, which can be a positive signal for employee retention and motivation.

Next Steps

• Future vesting increments for the remaining Restricted Stock Units will occur according to their respective schedules (e.g., quarterly over three or four years).

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction by a company executive involving the vesting of restricted stock units and a subsequent sale to cover tax obligations. Such transactions are common and do not typically provide new fundamental insights into the company's operational performance or strategic direction. Therefore, it does not warrant a change in investment recommendation based solely on this filing. An investor would hold their position, awaiting more substantive financial or operational news.

Keywords

Nurix Therapeutics, NRIX, Christine Ring, Chief Legal Officer, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Compensation, Sell to Cover, Stock Vesting, Biotechnology, Biopharmaceutical